AtaiBeckley (ATAI) Liabilities and Shareholders Equity (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Liabilities and Shareholders Equity came in at $264.9 million in Q1 2026, down 9.51% quarter-over-quarter from $292.7 million in Q4 2025.
AtaiBeckley (ATAI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
AtaiBeckley's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $264.9 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $264.9 million in Q1 2026; TTM through Mar 2026 was $717.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $292.7 million, up 83.66% from the prior year.
- Liabilities and Shareholders Equity retreated to $264.9 million in Q1 2026 per ATAI's latest filing, from $292.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $342.6 million in Q3 2022 to a low of $885000.0 in Q1 2021.
- A 5-year average of $178.6 million and a median of $239.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Biggest YoY gain for Liabilities and Shareholders Equity was 83.66% in 2025; the steepest drop was 83.66% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $159.4 million in 2024, then jumped by 83.66% to $292.7 million in 2025, then slipped by 9.51% to $264.9 million in 2026.
- Per Business Quant, the three latest ATAI Liabilities and Shareholders Equity figures stand at $264.9 million (Q1 2026), $292.7 million (Q4 2025), and $159.4 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | 239.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.88 Mn |
| Dec 31, 2025 | 292.72 Mn |
| Sep 30, 2025 | 239.82 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 159.39 Mn |
| Dec 31, 2024 | 159.39 Mn |
| Jun 30, 2024 | 215.78 Mn |
| Mar 31, 2024 | 269.12 Mn |
| Dec 31, 2023 | 293.48 Mn |
| Sep 30, 2023 | 308.22 Mn |
| Jun 30, 2023 | 253.60 Mn |
| Mar 31, 2023 | 280.72 Mn |
| Dec 31, 2022 | 305.44 Mn |
| Sep 30, 2022 | 342.60 Mn |
| Dec 31, 2021 | 4.76 Mn |
| Sep 30, 2021 | 885,000.00 |
| Jun 30, 2021 | 885,000.00 |
| Mar 31, 2021 | 885,000.00 |
| Dec 31, 2020 | 12.31 Mn |